22 下列血液系統作用藥物與其適應症之配對中,何者錯誤?
(A) anisindione:血小板減少症
(B) cilostazol:間歇跛
(C) enoxaparin:肺栓塞
(D) filgrastim:嚴重嗜中性白血球減少症
答案:登入後查看
統計: A(730), B(29), C(195), D(149), E(0) #417628
統計: A(730), B(29), C(195), D(149), E(0) #417628
詳解 (共 8 筆)
#867634
(A) anisindione:治療血栓症
32
1
#1593945
血小板減少症一般給予類固醇治療
23
1
#3742048
anisindione 抗血栓
cilostazol抑制PDE3:間歇跛
Parin抗凝血可治肺栓塞
Filstigram GCSF 增加白血球生成 治嗜中性白血球減少
10
0
#1019505
(D) Filgrastim: granulocyte colony-stimulating factor (G-CSF) analog used to stimulate the proliferation and differentiation of granulocytes.
10
0
#867596
Anisindione is a synthetic anticoagulant and an indanedione derivative. It prevents the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver by inhibiting the vitamin K–mediated gamma-carboxylation of precursor proteins.
5
2
#3138399
enoxaparin是一種低分子量肝素LMWH
4
1
#5198036
血小板減少 用-Oprelvekin是重組白細胞介素11,一种血小板生成生長因子,可直接刺激造血幹細胞和巨核細胞祖細胞的增殖,並誘導巨核細胞成熟,從而導致血小板生成增加。它以商標名Neumega銷售。 维基百科
0
0